Christopher M. Reilly

Modulation of renal disease in MRL/lpr mice by suberoylanilide hydroxamic acid.

Interferon regulatory factor-1 gene deletion decreases glomerulonephritis in MRL/lpr mice.

Clinical efficacy of buprenorphine to minimize distress in MRL/lpr mice.

The histone deacetylase inhibitor trichostatin A upregulates regulatory T cells and modulates autoimmunity in NZB/W F1 mice.

Protonated nanoparticle surface governing ligand tethering and cellular targeting.

Differential regulation of Foxp3 and IL-17 expression in CD4 T helper cells by IRAK-1.

Gestational exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin disrupts B-cell lymphopoiesis and exacerbates autoimmune disease in 24-week-old SNF1 mice.

Epigallocatechin-3-gallate (EGCG) attenuates inflammation in MRL/lpr mouse mesangial cells.

HDAC inhibition in lupus models.

Bio-distribution and in vivo antioxidant effects of cerium oxide nanoparticles in mice.

Histone deacetylase 9 deficiency protects against effector T cell-mediated systemic autoimmunity.

Deletion of PPAR-γ in immune cells enhances susceptibility to antiglomerular basement membrane disease.

HSP90 inhibition by 17-DMAG reduces inflammation in J774 macrophages through suppression of Akt and nuclear factor-κB pathways.

Heat shock protein 90 inhibition by 17-DMAG lessens disease in the MRL/lpr mouse model of systemic lupus erythematosus.

Catalytic nanoceria are preferentially retained in the rat retina and are not cytotoxic after intravitreal injection.

MicroRNAs implicated in the immunopathogenesis of lupus nephritis.

MicroRNA-let-7a expression is increased in the mesangial cells of NZB/W mice and increases IL-6 production in vitro.

Cellular and urinary microRNA alterations in NZB/W mice with hydroxychloroquine or prednisone treatment.

MicroRNA-let-7a promotes E2F-mediated cell proliferation and NFκB activation in vitro.

Class I and II histone deacetylase inhibition by ITF2357 reduces SLE pathogenesis in vivo.

Cutting Edge: Plasmacytoid Dendritic Cells in Late-Stage Lupus Mice Defective in Producing IFN-α.

HDAC expression and activity is upregulated in diseased lupus-prone mice.

Specific HDAC6 inhibition by ACY-738 reduces SLE pathogenesis in NZB/W mice.

Treatment with a selective histone deacetylase 6 inhibitor decreases lupus nephritis in NZB/W mice.

Selective Histone Deacetylase 6 Inhibition Normalizes B Cell Activation and Germinal Center Formation in a Model of Systemic Lupus Erythematosus.

Retinoic Acid Exerts Disease Stage-Dependent Effects on Pristane-Induced Lupus.

Regulation of neonatal IgA production by the maternal microbiota.

Altered Germinal-Center Metabolism in B Cells in Autoimmunity.